等待開盤 07-01 09:30:00 美东时间
+0.400
+2.50%
今日重点评级关注:Citizens:维持DBV Technologies"跑赢大市"评级,目标价从47美元升至55美元;康托·菲茨杰拉德:维持BioCryst制药"超配"评级,目标价从27美元升至29美元
今天 10:40
Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.
06-30 22:16
An announcement from DBV Technologies SA – American ( ($DBVT) ) is now availabl...
06-30 04:50
Voleon Capital discloses net short position in DBV Technologies Voleon Capital Management reported a 0.68% net short position in DBV Technologies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate an
06-16 21:41
DBV Technologies says JPMorgan Chase holds 12.32% stake JPMorgan Chase lifted its stake in DBV Technologies above 10% on June 4, holding 36,483,218 shares, or 12.32% of capital and voting rights. The move was driven by an increase in shares held by assimilation, largely tied to client financing and
06-09 17:53
DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the
06-03 16:24
Voleon Capital Management discloses net short position in DBV Technologies shares Voleon Capital Management disclosed a 0.7% net short position in DBV Technologies, dated June 1. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUB
06-02 22:49
JPMorgan cuts DBV Technologies stake to 8.97% from above 10% JPMorgan Chase disclosed multiple crossings of the 10% threshold in DBV Technologies during May 8-14, 2026. Latest filing showed a drop below 10% on May 14 to 26,557,807 shares, equal to 8.97% of capital and voting rights. Position was pre
05-29 19:13
DBV Technologies discloses JPMorgan beneficial stake at 8.97% of shares, votes JPMorgan Chase disclosed multiple moves across the 10% ownership threshold in DBV Technologies in May 2026, driven by changes in positions held by assimilation. The stake rose above 10% on May 8 to 32,344,236 shares, or 1
05-18 22:31
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从28美元升至49美元;HC Wainwright & Co.:维持Fate Therapeutics"买入"评级,目标价从5美元升至7美元
05-05 11:40